Literature DB >> 29680182

Changing trends in age and stage of colorectal cancer presentation in Ireland - From the nineties to noughties and beyond.

M F Ullah1, C A Fleming2, K Mealy1.   

Abstract

BACKGROUND: Recent studies report incidence of colorectal (CRC) in younger adults (<50 years old) is increasing, and these patients are more likely to present with advanced disease. We performed a population-based analysis of these trends in an Irish population.
METHODS: A retrospective analysis was performed of all patients with histologically confirmed CRC in Ireland, using data from the National Cancer Registry of Ireland (NCRI) [1994-2012, inclusive]. Trends in age-adjusted CRC incidence and stage at presentation were tabulated. Total and average age-adjusted annual percentage change (APC) in CRC rates were calculated using regression analysis, with age adjusted to the European standard population for trend analysis.
RESULTS: A total of 39,528 cases were included. Throughout the entire study period the most common age of presentation was 70-79 years (32.5%, n = 12 829) with Stage II (27.5%, n = 10 851) CRC. Overall, an increase in incidence of CRC of 2.1% was observed. A significantly increased incidence in patients aged 20-29 years (APC = 9.17%; total change = 4.2%; p = 0.003) was identified from 1994 to 2012. Overall, in patients <50 years, the incidence of stage I colorectal cancer at presentation significantly reduced from 23.5% to 11.6% (p = 0.01). This was associated with a significant parallel rise in stage IV disease (11%-23%, p = 0.02) in this age group.
CONCLUSION: Increasing incidence of CRC in younger patient groups is observed in an Irish population, with an increase in advanced staged disease at presentation seen. Further studies should focus on identifying causality for this trend and identify potential targets for prevention going forward.
Copyright © 2018 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer demographics; Cancer incidence; Colorectal cancer; Stage; Younger patients

Mesh:

Year:  2018        PMID: 29680182     DOI: 10.1016/j.surge.2018.03.006

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  6 in total

1.  A systematic review of methods to estimate colorectal cancer incidence using population-based cancer registries.

Authors:  Norah Alsadhan; Alaa Almaiman; Mar Pujades-Rodriguez; Cathy Brennan; Farag Shuweihdi; Sultana A Alhurishi; Robert M West
Journal:  BMC Med Res Methodol       Date:  2022-05-19       Impact factor: 4.612

2.  Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis.

Authors:  Jian-Feng Yao; Xiao-Jun Li; Li-Kun Yan; Sai He; Jian-Bao Zheng; Xiao-Rong Wang; Pei-Hua Zhou; Li Zhang; Guang-Bing Wei; Xue-Jun Sun
Journal:  J Biochem Mol Toxicol       Date:  2019-03-21       Impact factor: 3.642

3.  Age-period-cohort effects in utilization of diagnostic procedures leading to incidental colorectal cancer detection.

Authors:  Andrea Salvatori; Anita Andreano; Adriano Decarli; Antonio Giampiero Russo
Journal:  Eur J Cancer Prev       Date:  2022-01-01       Impact factor: 2.164

4.  MGP promotes CD8+ T cell exhaustion by activating the NF-κB pathway leading to liver metastasis of colorectal cancer.

Authors:  Dawei Rong; Guangshun Sun; Zhiying Zheng; Li Liu; Xiaoyuan Chen; Fan Wu; Yichao Gu; Yongjiu Dai; Weizhe Zhong; Xiaopei Hao; Chuanyong Zhang; Xiongxiong Pan; Jinhai Tang; Weiwei Tang; Xuehao Wang
Journal:  Int J Biol Sci       Date:  2022-03-06       Impact factor: 6.580

Review 5.  Incidence trends for twelve cancers in younger adults-a rapid review.

Authors:  Erica di Martino; Lesley Smith; Stephen H Bradley; Scott Hemphill; Judy Wright; Cristina Renzi; Rebecca Bergin; Jon Emery; Richard D Neal
Journal:  Br J Cancer       Date:  2022-02-07       Impact factor: 9.075

Review 6.  Metabolic dysfunction and early-onset colorectal cancer - how macrophages build the bridge.

Authors:  Katharina M Scheurlen; Adrian T Billeter; Stephen J O'Brien; Susan Galandiuk
Journal:  Cancer Med       Date:  2020-07-23       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.